REGISTER
Merck PD-1 Therapy Approved for 20th Indication in China
Merck’s pembrolizumab has been approved in China with carboplatin and paclitaxel followed by maintenance monotherapy for first-line treatment of adults with dMMR primary advanced or recurrent endometrial carcinoma, becoming the first PD-1 inhibitor approved in China for this setting.

On February 6, Merck announced that its PD-1 inhibitor pembrolizumab had been approved by the NMPA in China, in combination with carboplatin and paclitaxel for first-line treatment of adult patients with mismatch repair-deficient (dMMR) primary advanced or recurrent endometrial carcinoma, followed by pembrolizumab monotherapy maintenance.

According to the press release, this is pembrolizumab’s 20th approved indication in China and also the first PD-1 inhibitor approved in China for first-line treatment of advanced or recurrent endometrial carcinoma.

The new approval was based on data from the Phase III clinical trial KEYNOTE-868 (NRG-GY018). In the trial, compared with placebo plus carboplatin and paclitaxel followed by placebo alone, KEYTRUDA plus carboplatin and paclitaxel followed by KEYTRUDA alone reduced the risk of disease progression or death by 40% in mismatch repair-proficient patients and by 70% in mismatch repair-deficient patients.

Endometrial carcinoma is a common gynecologic malignancy, and its incidence is rising in China. Although the age-standardized five-year survival rate has continued to improve in recent years, treatment options remain limited and prognosis poor for patients with advanced or recurrent disease, leaving a major unmet need in clinical practice.

This newly approved indication brings a new first-line treatment option to endometrial carcinoma patients in China and provides clinicians with more individualized choices.

0
0
Loading